Sun Pharma Eyes USD 10 Billion Organon Acquisition to Boost US Presence

• Sun Pharmaceutical Industries Ltd is reportedly evaluating a USD 10 billion acquisition of US-based Organon, a women's healthcare and biosimilars specialist.
• This potential deal, including debt, would be India's largest cross-border pharmaceutical acquisition and transformative for Sun Pharma's US market position.
• Organon, spun off from MSD in 2021, has a market capitalization of USD 2.28 billion and has seen its shares fluctuate due to sales malpractice reports and takeover speculation.
• The acquisition would integrate Organon's women's health brands (e.g., Nexplanon) and biosimilars portfolio (e.g., Renflexis) into Sun Pharma's US offerings.
• Sun Pharma has clarified that reports regarding the Organon acquisition are speculative, and negotiations may not necessarily lead to a deal.

Why It Matters: Sun Pharma is reportedly considering a USD 10 billion acquisition of Organon to significantly expand its US market presence.